retatrutide triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide: The "Triple G" Peptide
Pay in 4 interest-free payments of $5.46 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9



























Krachtdoppen"" loading="lazy"/>
/504c830daeb145a4a4f3948e14da746b/rules-and-useful-tips-for-carrying-cigarettes-on-airplanes-1200-x-630.jpg)
